We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Denali Therapeutics
DNLI
$3.74B
| $5M | 0.03% |
+63,781
| New | +$3.95M |
|
402
Robert Half
RHI
$4.07B
| $4.99M | 0.03% |
56,127
+51,425
| +1,094% | +$4.48M |
|
403
US Bancorp
USB
$98.9B
| $4.95M | 0.03% |
86,836
-9,004
| -9% | -$528K |
|
404
Kimberly-Clark
KMB
$37B
| $4.93M | 0.03% |
36,829
-26,313
| -42% | -$3.51M |
|
405
Restaurant Brands International
QSR
$25.8B
| $4.9M | 0.03% |
75,940
-86,009
| -53% | -$5.79M |
|
406
Mid-America Apartment Communities
MAA
$15.5B
| $4.9M | 0.03% |
29,075
+22,108
| +317% | +$3.52M |
|
407
Pfizer
PFE
$141B
| $4.89M | 0.03% |
124,825
-24,869
| -17% | -$967K |
|
|
FISV
408
Fiserv Inc
FISV
$27.9B
| $4.86M | 0.03% |
45,495
+11,818
| +35% | +$1.37M |
|
409
T-Mobile US
TMUS
$190B
| $4.8M | 0.03% |
33,151
+5,466
| +20% | +$754K |
|
|
KNL
410
DELISTED
Knoll, Inc.
KNL
| $4.8M | 0.03% |
+184,616
| New | +$4.4M |
|
411
Neurogene
NGNE
$691M
| $4.73M | 0.03% |
25,601
+25,599
| +1,279,950% | +$5.66M |
|
412
Bruker
BRKR
$9.14B
| $4.72M | 0.03% |
62,128
-1,071
| -2% | -$74.8K |
|
413
Ultragenyx Pharmaceutical
RARE
$2.65B
| $4.72M | 0.03% |
49,480
-48,949
| -50% | -$5.1M |
|
414
Equity Residential
EQR
$25.2B
| $4.71M | 0.03% |
32,412
-4,809
| -13% | -$364K |
|
415
ResMed
RMD
$29.5B
| $4.66M | 0.03% |
18,907
+1,132
| +6% | +$238K |
|
|
JBGS
416
JBG SMITH
JBGS
$832M
| $4.63M | 0.03% |
+146,796
| New | +$4.79M |
|
417
Dell
DELL
$276B
| $4.6M | 0.03% |
91,143
-143,086
| -61% | -$7.18M |
|
|
BHVN
418
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.56M | 0.03% |
47,005
-2,062
| -4% | -$167K |
|
419
Airbnb
ABNB
$87.2B
| $4.56M | 0.03% |
+29,759
| New | +$4.67M |
|
420
Etsy
ETSY
$7.96B
| $4.56M | 0.03% |
22,136
-27,016
| -55% | -$5M |
|
421
Clorox
CLX
$11.8B
| $4.49M | 0.03% |
19,177
-106,004
| -85% | -$19.3M |
|
422
Digital Turbine
APPS
$1.04B
| $4.48M | 0.03% |
58,930
+31,630
| +116% | +$2.26M |
|
423
Canadian National Railway
CNI
$78B
| $4.43M | 0.03% |
41,938
-34,017
| -45% | -$3.75M |
|
424
Revvity
RVTY
$12.1B
| $4.41M | 0.03% |
28,531
+28,514
| +167,729% | +$4.01M |
|
425
NetEase
NTES
$79.2B
| $4.4M | 0.03% |
38,150
-6,000
| -14% | -$661K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.